• In early January 2026, Medtronic reported real-world data in Diabetes Care showing its MiniMed 780G insulin pump helped users reach American Diabetes Association time-in-range goals even on days when mealtime boluses were missed, while an analyst at William Blair upgraded the stock to Outperform citing momentum across several new product launches.
• The Diabetes Care analysis is especially important because it suggests optimized MiniMed 780G settings may meaningfully ease the day-to-day burden of insulin dosing for people who occasionally miss meal boluses, a frequent challenge in diabetes management.
• Next, we will examine how this MiniMed 780G real-world performance data could influence Medtronic’s broader investment narrative built around innovation and growth.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Medtronic Investment Narrative Recap

To own Medtronic, you generally need to believe its broad innovation engine, including diabetes technology, can offset margin pressure and uneven segment performance. The new MiniMed 780G real-world data supports the strength of its Diabetes franchise but does not, by itself, materially change the near term execution risk around major product ramp-ups and the planned Diabetes separation.

The William Blair upgrade to Outperform, tied to momentum in launches like Hugo robotics and Symplicity Spyral RDN, aligns with the idea that Medtronic’s biggest short term catalyst remains successful execution of its new product ramps and related margin improvement, with the MiniMed 780G data reinforcing confidence in the Diabetes part of that story.

Yet investors should be aware that continued margin pressure from product mix and large scale manufacturing ramps could still...

Medtronic's narrative projects $40.0 billion revenue and $6.3 billion earnings by 2028.

Uncover how Medtronic's forecasts yield a $110.97 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Eight members of the Simply Wall St Community currently see fair value for Medtronic between US$95 and about US$111, reflecting a wide span of individual assessments. Against this backdrop, the execution risk in Medtronic’s major new product ramp ups, including Diabetes devices and robotics, may influence which of these valuation views proves closer to how the market ultimately prices the business, so it is worth exploring several of these perspectives.

Explore 8 other fair value estimates on Medtronic - why the stock might be worth as much as 11% more than the current price!

Build Your Own Medtronic Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.